



Lisata Therapeutics: WBB Securities – Initiation report

December 29, 2022

On September 15, 2022, Caladrius Biosciences, Inc. (CLBS) and Cend Therapeutics, Inc. (private) announced the closing of a merger between the two companies. The merged company now operates as Lisata Therapeutics, Inc. (LSTA). Their development efforts focus primarily on advancing the CendR Platform™ product candidates in a range of oncology indications, in addition to existing CD34+ development programs begun under CLBS. WBB has covered LSTA's precursor companies since 2010.

[Click here to read full report.](#)